ferumoxytol
information and resources from the National Cancer Institute
NCI Thesaurus | ferumoxytol
A superparamagnetic iron oxide nanoparticle coated with a low molecular weight semi-synthetic carbohydrate, polyglucose sorbitol carboxymethyl ether, with potential anti-anemic and imaging properties. After intravenous administration, ferumoxytol replaces iron stores with fewer side effects compared to the use of oral iron. In addition, this agent generates T1 relaxation, producing a magnetic field and enhancing T2 relaxation, thereby darkening contrast media-containing structures in magnetic resonance imaging (MRI). Due to small particle size, ferumoxytol remains in the intravasculature for a prolonged period and so may be used as a blood pool agent. NCI Thesaurus | ferumoxytol
A superparamagnetic iron oxide nanoparticle coated with a low molecular weight semi-synthetic carbohydrate, polyglucose sorbitol carboxymethyl ether, with potential anti-anemic and imaging properties. After intravenous administration, ferumoxytol replaces iron stores with fewer side effects compared to the use of oral iron. In addition, this agent generates T1 relaxation, producing a magnetic field and enhancing T2 relaxation, thereby darkening contrast media-containing structures in magnetic resonance imaging (MRI). Due to small particle size, ferumoxytol remains in the intravasculature for a prolonged period and so may be used as a blood pool agent.
|
|
|
|
news articles
Advanced Magnetics Announces Design of Phase III Iron Therapy ... Mar 3, 2006
PR Newswire (press release), ...(Amex: AVM) today announced the design of its Phase III development program for ferumoxytol as an intravenous iron replacement therapeutic following a series ...
Advanced Magnetics, Inc. Announces Common Stock Offering Mar 6, 2006
Yahoo! News (press release) The proceeds from the transaction will be used to fund clinical development programs, including continued development of ferumoxytol as an iron replacement ...
Advanced Magnetics maps out Phase 3 iron replacement therapy ... Mar 3, 2006
Boston Mass High Tech, ...has designed its Phase 3 development program for ferumoxytol as an intravenous iron replacement therapeutic, following discussions with the US Food and Drug ...
Cytogen Announces Schedule for Clinical Data Presentations at ... Mar 23, 2006
PR Newswire (press release), United States marketing rights to COMBIDEX(R) (ferumoxtran-10) for all applications, and the exclusive right to market and sell ferumoxytol (previously Code ...
(PRN) - Coalition America, Inc.'s CEO and Chairman Elected to ... Mar 3, 2006
Bolsamania.com, Their Own Restaurants ... [+. PRN) - Advanced Magnetics Announces Design of Phase III Iron Therapy Program for Ferumoxytol ... [+.
Cytogen to Raise $13.3 Million Through Sale of Common Stock and ... Dec 13, 2005
PR Newswire (press release), United States marketing rights to COMBIDEX(R) (ferumoxtran-10) for all applications, and the exclusive right to market and sell ferumoxytol (previously Code ...
|
|
